Xilio Therapeutics Q4 2023 Earnings Report $1.02 -0.02 (-1.92%) (As of 12/3/2024 ET) Xilio Therapeutics EPS ResultsActual EPS-$0.64Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AXilio Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AXilio Therapeutics Announcement DetailsQuarterQ4 2023Date4/1/2024TimeN/AConference Call ResourcesPress ReleaseXLO Earnings HistoryPowered by Even Trump can’t stop what’s coming. (Ad)No matter who sits in the White House over the next four years, a series of events has been triggered that could devastate millions of Americans. These events have caused five major cracks in our economy... That's why I have moved 7-figures of my own money out of the stock market.Watch my emergency briefing here >>> Xilio Therapeutics Earnings HeadlinesXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3 at 4:30 PM | globenewswire.comShort Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Declines By 89.4%November 28, 2024 | americanbankingnews.comMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.December 4, 2024 | Brownstone Research (Ad)Promising Pipeline and Financial Stability Drive Buy Rating for Xilio TherapeuticsNovember 9, 2024 | markets.businessinsider.comXilio Therapeutics Reports Q3 2024 Progress and FinancialsNovember 9, 2024 | markets.businessinsider.comXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial ResultsNovember 8, 2024 | finance.yahoo.comSee More Xilio Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xilio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xilio Therapeutics and other key companies, straight to your email. Email Address About Xilio TherapeuticsXilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.View Xilio Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Upcoming Earnings Toronto-Dominion Bank (12/5/2024)Canadian Imperial Bank of Commerce (12/5/2024)Bank of Montreal (12/5/2024)Oracle (12/9/2024)Adobe (12/11/2024)Broadcom (12/12/2024)Costco Wholesale (12/12/2024)Accenture (12/17/2024)Micron Technology (12/18/2024)Paychex (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
